Radius Health to Present at Goldman Sachs 40th Annual Global Healthcare Conference
04. Juni 2019 09:00 ET
|
Radius Health Inc.
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and...
Radius Health to Present at Bank of America Merrill Lynch Health Care Conference 2019
10. Mai 2019 16:42 ET
|
Radius Health Inc.
WALTHAM, Mass., May 10, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and...
Radius Health Announces First Quarter 2019 Operating Results
08. Mai 2019 07:56 ET
|
Radius Health Inc.
TYMLOS® U.S. net sales were $29.8 million in the first quarter of 2019 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic osteoporosis market...
Radius Health to Announce First Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, May 8, 2019
23. April 2019 09:00 ET
|
Radius Health Inc.
WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019. The Company...
Radius Health to Present Two Posters at AACE 2019 Annual Meeting
17. April 2019 08:00 ET
|
Radius Health Inc.
WALTHAM, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
23. März 2019 12:45 ET
|
Radius Health Inc.
-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies...
Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
18. März 2019 08:00 ET
|
Radius Health Inc.
WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
Radius Health to Present at Cowen 39th Annual Healthcare Conference
11. März 2019 16:30 ET
|
Radius Health Inc.
WALTHAM, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the...
Radius Health to Participate in 2019 Credit Suisse Global Healthcare Conference
01. März 2019 09:00 ET
|
Radius Health Inc.
WALTHAM, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global...
Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
28. Februar 2019 16:05 ET
|
Radius Health Inc.
TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million. ...